The earnings call reflects a generally positive sentiment with significant revenue growth, strategic partnerships, and a strong cash position outweighing the increased operating expenses.

Company Guidance -

Q2 2025

During the first quarter of 2025, Zymeworks reported a net loss of $22.6 million, a decrease from $31.7 million in the same period of 2024, due to an increase in revenue to $27.1 million from $10 million, partly driven by milestone revenues from GSK and Daiichi Sankyo. Operating expenses rose by 10% to $52.7 million, mainly from increased R&D expenses, while cash resources slightly decreased to $321.6 million. The company anticipates its cash, combined with expected regulatory milestones, to fund operations into the second half of 2027. Key developments included six poster presentations at AACR, highlighting progress in their antibody drug conjugate and T-cell engager pipeline, and anticipated presentations at upcoming medical conferences. The potential approval of zanidatamab by the EMA could lead to increased royalty revenue, while collaborations like the one with JNJ could yield substantial future financial benefits.

Significant Revenue Growth

Zymeworks reported a revenue increase to $27.1 million for Q1 2025, up from $10 million in the same period in 2024, largely driven by milestone revenues from partnerships with GSK and Daiichi Sankyo.

Positive Opinion from EMA

The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion for the approval of zanidatamab for advanced HER2+ biliary tract cancer, which could increase royalty revenues for Zymeworks.

Strong Pipeline and Partnerships

Zymeworks presented six posters at the AACR Annual Meeting, showcasing its progress in antibody drug conjugates and T-cell engagers. Notable partnerships with Jazz and JNJ highlight ongoing and future developments.

Reduction in Net Loss

Net loss decreased to $22.6 million for Q1 2025 from $31.7 million in Q1 2024, attributed to increased revenue.

Robust Cash Position

Zymeworks had $321.6 million in cash resources as of March 31, 2025, expected to fund operations into the second half of 2027.

Zymeworks (ZYME) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ZYME Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	-0.49 / -	-0.49	―	―	―
May 08, 2025	2025 (Q1)	-0.68 / -0.30	-0.42	28.57% (+0.12)
Mar 05, 2025	2024 (Q4)	-0.10 / -0.31	-0.2	-55.00% (-0.11)
Oct 31, 2024	2024 (Q3)	-0.40 / -0.39	-0.41	4.88% (+0.02)
Aug 01, 2024	2024 (Q2)	-0.42 / -0.49	-0.76	35.53% (+0.27)
May 02, 2024	2024 (Q1)	-0.32 / -0.42	-0.37	-13.51% (-0.05)
Mar 06, 2024	2023 (Q4)	-0.41 / -0.20	4.65	-104.30% (-4.85)
Nov 07, 2023	2023 (Q3)	-0.47 / -0.41	-0.72	43.06% (+0.31)
Aug 10, 2023	2023 (Q2)	-0.47 / -0.76	-0.97	21.65% (+0.21)
May 08, 2023	2023 (Q1)	-0.54 / -0.37	-1.19	68.91% (+0.82)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ZYME Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	$11.32	$11.30	-0.18%
Mar 05, 2025	$13.18	$12.13	-7.97%
Oct 31, 2024	$13.70	$13.28	-3.07%
Aug 01, 2024	$10.11	$10.20	+0.89%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Zymeworks Inc (ZYME) report earnings?

Zymeworks Inc (ZYME) is schdueled to report earning on Aug 07, 2025, Before Open (Confirmed).

What is Zymeworks Inc (ZYME) earnings time?

Zymeworks Inc (ZYME) earnings time is at Aug 07, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ZYME EPS forecast?

ZYME EPS forecast for the fiscal quarter 2025 (Q2) is -0.49.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing